Regenerative Medicine News

JOIN ARM FOR THE 9th ANNUAL DINNER & LEGISLATIVE FLY-IN! NEW TO THIS YEAR'S AGENDA THERE WILL BE A FULL DAY OF MEETINGS AND PROGRAMMING LEADING UP TO THE ANNUAL DINNER INCLUDING AN RMAT POLICY LUNCH BRIEFING, A STATE OF THE INDUSTRY MID-YEAR UPDATE AND AN INTERACTIVE PANEL DISCUSSION FEATURING THE PATIENT EXPERIENCE.
The 2017 Annual Data Report details industry-specific statistics and trends from more than 850 leading cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide.
October 18, 2017 - (Quad) - Quad Technologies announced today the U.S. Patent and Trademark Office has awarded the company a new U.S. Patent, No. 9,790,467, titled “Methods and Compositions for activation or expansion of T lymphocytes”. According to Quad Technologies CEO Sean Kevlahan, the patent relates to a scalable T-lymphocyte culture reagent that helps streamline CAR-T by eliminating the need for magnetic beads and the downstream “debeading” unit operation.
Join ARM on Monday, June 4 in Boston for a private evening reception bringing together key stakeholders representing the cell and gene therapy sector. RSVP is required - reserve your spot today!
pornpornpornoA playback is now available of ARM's webinar "Understanding the 21st Century Cures Act for Cell & Gene Therapies" held on February 2 with representatives from FDA. Visit the webpage and access the playback.
porno izleJoin ARM, along with the Hemophilia Federation of America and the National Hemophilia Foundation, in Washington, D.C. on December 13 to learn about the latest scientific progress and delivery challenges associated with hemophilia and other inherited blood disorders. 

Pages